Floatz logo

9-valent human papillomavirus recombinant vaccine

HPV-Related Carcinoma

Shanghai Bovax Biotechnology Co., Ltd.vaccinePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the HPV-Related Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Christian Hinrichs
Phase 2B
Fludarabine
Christian Hinrichs
Phase 2B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
Retifanlimab
Jennifer Dorth
Phase 2CCC
scg142
SCG Cell Therapy Pte. Ltd.
Phase 1/2CCC

View all 18 →

Same molecule, other indications

9-valent human papillomavirus recombinant vaccine is also rated in:

anal canal carcinoma in situDormant
BB
Indicative ·
66 / 100
View asset →
anogenital human papillomavirus infectionDormant
B
Indicative ·
60 / 100
View asset →
penile cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →